R&D News | pharmaphorum

News

Amgen defeated in lengthy PCSK9 feud with Sanofi

The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower cholesterol has come to an end, with San

News

Servier doubles up on ‘digital twin’ alliance with Aitia

French pharma group Servier has formed a second partnership with Aitia focusing on the use of artificial intelligence and

News

PTC eyes filings for PKU therapy after phase 3 win

PTC Therapeutics is on track to file for approval of a new therapy for rare disease phenylketonuria after a positive phase 3 readout that could extend its product portfoli

News

AZ posts first-line combo data for lung cancer drug Tagrisso

AstraZeneca’s top-selling drug Tagrisso is already widely used on its own as a first-line treatment for EGFR-mutated lung cancer, but new data suggests there can be benefi

News

Roche’s BTK drug fenebrutinib hits the mark in MS

Roche has made its case for BTK inhibitor fenebrutinib as a potential new oral therapy for multiple sclerosis, with a phase 2 readout that it says shows significant improv

News

Boundless Bio raises $100m for circular DNA cancer therapy

Boundless Bio’s plans to develop a new class of cancer therapies targeting DNA found outside the nucleus of malignant cells have been boosted by a $100 million fundraising

Amgen defeated in lengthy PCSK9 feud with Sanofi

Servier doubles up on ‘digital twin’ alliance with Aitia

PTC eyes filings for PKU therapy after phase 3 win

AZ posts first-line combo data for lung cancer drug Tagrisso

Roche’s BTK drug fenebrutinib hits the mark in MS

Boundless Bio raises $100m for circular DNA cancer therapy

Pharvaris plans filings for HAE drug after pivotal trial win

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks